The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.
[INTRODUCTION] The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain.
- 95% CI 0.59-0.73
- HR 0.66
- 연구 설계 meta-analysis
APA
Zhang F, Luo Z, et al. (2025). The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.. Expert review of anticancer therapy, 25(9), 1099-1109. https://doi.org/10.1080/14737140.2025.2522981
MLA
Zhang F, et al.. "The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.." Expert review of anticancer therapy, vol. 25, no. 9, 2025, pp. 1099-1109.
PMID
40531349
Abstract
[INTRODUCTION] The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume mHSPC.
[RESEARCH DESIGN AND METHODS] Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model.
[RESULTS] Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All < 0.05).
[CONCLUSIONS] Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting.
[REGISTRATION] (CRD420251028079).
[RESEARCH DESIGN AND METHODS] Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model.
[RESULTS] Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All < 0.05).
[CONCLUSIONS] Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting.
[REGISTRATION] (CRD420251028079).
MeSH Terms
Humans; Male; Prostatic Neoplasms; Androstenes; Randomized Controlled Trials as Topic; Clinical Trials, Phase III as Topic; Progression-Free Survival; Neoplasm Metastasis; Survival Rate; Proportional Hazards Models; Antineoplastic Agents; Survival Analysis; Treatment Outcome; Tumor Burden
같은 제1저자의 인용 많은 논문 (5)
- Synergistic targeting and stimuli-responsive drug delivery from a dual-network injectable hydrogel for enhanced breast cancer treatment.
- Molecular characterization of early-stage multi-primary lung adenocarcinoma by transcriptome sequencing-a retrospective study.
- First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.
- The Role of Neutrophils in Non-Alcoholic Fatty Liver Disease: Mechanisms and Clinical Significance.
- Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data.